Literature DB >> 7935812

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma.

B Ensoli1, R Gendelman, P Markham, V Fiorelli, S Colombini, M Raffeld, A Cafaro, H K Chang, J N Brady, R C Gallo.   

Abstract

Basic fibroblast growth factor (bFGF) and human immunodeficiency virus type 1 (HIV-1) Tat protein synergize in inducing angiogenic Kaposi's sarcoma-like lesions in mice. Synergy is due to Tat, which enhances endothelial cell growth and type-IV collagenase expression in response to bFGF mimicking extracellular matrix proteins. The bFGF, extracellular Tat and Tat receptors are present in HIV-1-associated KS, which may explain the higher frequency and aggressiveness of this form compared to classical Kaposi's sarcoma where only bFGF is present.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7935812     DOI： 10.1038/371674a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


  133 in total

1.  Identification of the immediate-early transcripts of Kaposi's sarcoma-associated herpesvirus.

Authors:  F X Zhu; T Cusano; Y Yuan
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells.

Authors:  P Monini; F Carlini; M Stürzl; P Rimessi; F Superti; M Franco; G Melucci-Vigo; A Cafaro; D Goletti; C Sgadari; S Butto'; P Leone; C Chiozzini; C Barresi; A Tinari; A Bonaccorsi; M R Capobianchi; M Giuliani; A di Carlo; M Andreoni; G Rezza; B Ensoli
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

3.  Human herpesvirus-8-transformed endothelial cells have functionally activated vascular endothelial growth factor/vascular endothelial growth factor receptor.

Authors:  Rizwan Masood; Ethel Cesarman; D Lynne Smith; Parkash S Gill; Ornella Flore
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

4.  Human immunodeficiency virus replication in a primary effusion lymphoma cell line stimulates lytic-phase replication of Kaposi's sarcoma-associated herpesvirus.

Authors:  V Varthakavi; P J Browning; P Spearman
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma.

Authors:  Brian R Lane; Jianguo Liu; Paul J Bock; Dominique Schols; Michael J Coffey; Robert M Strieter; Peter J Polverini; David M Markovitz
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

6.  Tat protein induces self-perpetuating permissivity for productive HIV-1 infection.

Authors:  C J Li; Y Ueda; B Shi; L Borodyansky; L Huang; Y Z Li; A B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

7.  Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene.

Authors:  G Altavilla; A Caputo; M Lanfredi; C Piola; G Barbanti-Brodano; A Corallini
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 8.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

9.  Identification of specific molecular structures of human immunodeficiency virus type 1 Tat relevant for its biological effects on vascular endothelial cells.

Authors:  S Mitola; R Soldi; I Zanon; L Barra; M I Gutierrez; B Berkhout; M Giacca; F Bussolino
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

10.  Human immunodeficiency virus type 1 Tat accelerates Kaposi sarcoma-associated herpesvirus Kaposin A-mediated tumorigenesis of transformed fibroblasts in vitro as well as in nude and immunocompetent mice.

Authors:  Xiuying Chen; Lin Cheng; Xuemei Jia; Yi Zeng; Shuihong Yao; Zhigang Lv; Di Qin; Xin Fang; Yongliang Lei; Chun Lu
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.